Chemistry:Balipodect
From HandWiki
Balipodect (INN, USAN; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia.[1][2][3]
It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.[4]
The drug reached phase 2 clinical trials for this indication but its development was discontinued.[1][2] It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.[5][6][7]
See also
- Mardepodect
- MK-8189
- Osoresnontrine
- Papaverine
- Rolipram
- Tofisopam
References
- ↑ 1.0 1.1 "Balipodect". 30 January 2018. https://adisinsight.springer.com/drugs/800036538.
- ↑ 2.0 2.1 "Delving into the Latest Updates on Balipodect with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/a81359946a1d416886e944e1e1d05839.
- ↑ "TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia". CNS Neuroscience & Therapeutics 24 (7): 604–614. July 2018. doi:10.1111/cns.12798. PMID 29318783.
- ↑ "PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?". Frontiers in Neuroscience 14. 2020. doi:10.3389/fnins.2020.600178. PMID 33551724.
- ↑ "Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.1057083. PMID 36506513.
- ↑ "Progress in mechanistically novel treatments for schizophrenia". RSC Medicinal Chemistry 12 (9): 1459–1475. September 2021. doi:10.1039/d1md00096a. PMID 34671731.
- ↑ "Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities". CNS Spectrums 24 (S1): 38–69. August 2019. doi:10.1017/S109285291900124X. PMID 31482779.
 |  |
